402 related articles for article (PubMed ID: 16034459)
1. Herpes simplex virus type-1 amplicon vectors for vaccine generation in acute lymphoblastic leukemia.
Zibert A; Thomassen A; Müller L; Nguyen L; Glouchkova L; Fraefel C; Roskrow M; Meisel R; Dilloo D
Gene Ther; 2005 Dec; 12(23):1707-17. PubMed ID: 16034459
[TBL] [Abstract][Full Text] [Related]
2. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status.
Douin-Echinard V; Bornes S; Rochaix P; Tilkin AF; Peron JM; Bonnet J; Favre G; Couderc B
Cancer Gene Ther; 2000 Dec; 7(12):1543-56. PubMed ID: 11228533
[TBL] [Abstract][Full Text] [Related]
3. Use of herpes simplex virus type 1-based amplicon vector for delivery of small interfering RNA.
Sabbioni S; Callegari E; Manservigi M; Argnani R; Corallini A; Negrini M; Manservigi R
Gene Ther; 2007 Mar; 14(5):459-64. PubMed ID: 17051250
[TBL] [Abstract][Full Text] [Related]
4. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
[TBL] [Abstract][Full Text] [Related]
5. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
Todo T; Martuza RL; Dallman MJ; Rabkin SD
Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
[TBL] [Abstract][Full Text] [Related]
6. HSV-1 amplicon viral vector-mediated gene transfer to human bone marrow-derived mesenchymal stem cells.
Ho IA; Chan KY; Miao L; Shim WS; Guo CM; Cheang P; Hui KM; Lam PY
Cancer Gene Ther; 2008 Sep; 15(9):553-62. PubMed ID: 18535622
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus.
Kohno SI; Luo C; Nawa A; Fujimoto Y; Watanabe D; Goshima F; Tsurumi T; Nishiyama Y
Cancer Gene Ther; 2007 Nov; 14(11):918-26. PubMed ID: 17693992
[TBL] [Abstract][Full Text] [Related]
8. Optimal purification method for Herpes-based viral vectors that confers minimal cytotoxicity for systemic route of vector administration.
Sia KC; Wang GY; Ho IA; Khor HY; Miao L; Hui KM; Lam PY
J Virol Methods; 2007 Feb; 139(2):166-74. PubMed ID: 17074404
[TBL] [Abstract][Full Text] [Related]
9. Generation of stable retrovirus packaging cell lines after transduction with herpes simplex virus hybrid amplicon vectors.
Sena-Esteves M; Hampl JA; Camp SM; Breakefield XO
J Gene Med; 2002; 4(3):229-39. PubMed ID: 12112640
[TBL] [Abstract][Full Text] [Related]
10. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.
Liu BL; Robinson M; Han ZQ; Branston RH; English C; Reay P; McGrath Y; Thomas SK; Thornton M; Bullock P; Love CA; Coffin RS
Gene Ther; 2003 Feb; 10(4):292-303. PubMed ID: 12595888
[TBL] [Abstract][Full Text] [Related]
11. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models.
Terada K; Wakimoto H; Tyminski E; Chiocca EA; Saeki Y
Gene Ther; 2006 Apr; 13(8):705-14. PubMed ID: 16421599
[TBL] [Abstract][Full Text] [Related]
12. Herpes simplex virus (HSV) amplicon-mediated codelivery of secondary lymphoid tissue chemokine and CD40L results in augmented antitumor activity.
Tolba KA; Bowers WJ; Muller J; Housekneckt V; Giuliano RE; Federoff HJ; Rosenblatt JD
Cancer Res; 2002 Nov; 62(22):6545-51. PubMed ID: 12438249
[TBL] [Abstract][Full Text] [Related]
13. Simian immunodeficiency virus vector pseudotypes differ in transduction efficiency and target cell specificity in brain.
Liehl B; Hlavaty J; Moldzio R; Tonar Z; Unger H; Salmons B; Günzburg WH; Renner M
Gene Ther; 2007 Sep; 14(18):1330-43. PubMed ID: 17611586
[TBL] [Abstract][Full Text] [Related]
14. Combination gene therapy using multiple immunomodulatory genes transferred by a defective infectious single-cycle herpes virus in squamous cell cancer.
Kim SH; Carew JF; Kooby DA; Shields J; Entwisle C; Patel S; Shah JP; Fong Y
Cancer Gene Ther; 2000 Sep; 7(9):1279-85. PubMed ID: 11023201
[TBL] [Abstract][Full Text] [Related]
15. HSV-1 amplicon vectors that direct the in situ production of foot-and-mouth disease virus antigens in mammalian cells can be used for genetic immunization.
D'Antuono A; Laimbacher AS; La Torre J; Tribulatti V; Romanutti C; Zamorano P; Quattrocchi V; Schraner EM; Ackermann M; Fraefel C; Mattion N
Vaccine; 2010 Oct; 28(46):7363-72. PubMed ID: 20851082
[TBL] [Abstract][Full Text] [Related]
16. Establishment of a novel foreign gene delivery system combining an HSV amplicon with an attenuated replication-competent virus, HSV-1 HF10.
Zhang L; Daikoku T; Ohtake K; Ohtsuka J; Nawa A; Kudoh A; Iwahori S; Isomura H; Nishiyama Y; Tsurumi T
J Virol Methods; 2006 Nov; 137(2):177-83. PubMed ID: 16854473
[TBL] [Abstract][Full Text] [Related]
17. Coexpression of CD40L and CD70 by semiallogenic tumor cells induces anti-tumor immunity.
Cormary C; Hiver E; Mariamé B; Favre G; Tilkin-Mariamé AF
Cancer Gene Ther; 2005 Dec; 12(12):963-72. PubMed ID: 15956983
[TBL] [Abstract][Full Text] [Related]
18. Combined HSV-1 recombinant and amplicon piggyback vectors: replication-competent and defective forms, and therapeutic efficacy for experimental gliomas.
Pechan PA; Herrlinger U; Aghi M; Jacobs A; Breakefield XO
J Gene Med; 1999; 1(3):176-85. PubMed ID: 10738566
[TBL] [Abstract][Full Text] [Related]
19. Variability in infectivity of primary cell cultures of human brain tumors with HSV-1 amplicon vectors.
Rueger MA; Winkeler A; Miletic H; Kaestle C; Richter R; Schneider G; Hilker R; Heneka MT; Ernestus RI; Hampl JA; Fraefel C; Jacobs AH
Gene Ther; 2005 Apr; 12(7):588-96. PubMed ID: 15674397
[TBL] [Abstract][Full Text] [Related]
20. Double-copy bicistronic retroviral vector platform for gene therapy and tissue engineering: application to melanoma vaccine development.
Wiznerowicz M; Fong AZ; Mackiewicz A; Hawley RG
Gene Ther; 1997 Oct; 4(10):1061-8. PubMed ID: 9415312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
